JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Elenco Azioni・Sanofi

Sanofi

Chiusa

43.37 0.18

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

43.08

Massimo

43.52

Metriche Chiave
By Trading Economics
Entrata	2.4B 1.6B
Vendite	-961M 11B
P/E Media del settore	19.885 67.147
EPS	1.102
Margine di Profitto	14.354
Dipendenti	74,846
EBITDA	-1.1B 2.7B

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	+22.26% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-11B 104B
Apertura precedente	43.19
Chiusura precedente	43.37

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bearish Evidence

51.665 / 52.38 Supporto e resistenza

Sanofi Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 apr 2026, 06:12 UTC

Utili

Sanofi Posts Higher Sales Amid Leadership Transition

12 feb 2026, 12:40 UTC

I principali Market Mover

Sanofi Shares Fall After CEO Change

29 gen 2026, 11:35 UTC

Utili

Sanofi Remains Committed to Vaccines After Mixed Year for Drug Pipeline -- Update

29 apr 2026, 12:01 UTC

Utili

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

27 apr 2026, 09:32 UTC

Discorsi di Mercato

Utili

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 apr 2026, 09:19 UTC

Discorsi di Mercato

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

23 apr 2026, 05:34 UTC

Utili

Sanofi: 2026 Expectations Are at Constant Exchange Rates

23 apr 2026, 05:34 UTC

Utili

Sanofi Sees Business EPS Growth Slightly Faster Than Sales in 2026

23 apr 2026, 05:34 UTC

Utili

Sanofi Sees Sales Growth by a High Single-Digit Percentage in 2026

23 apr 2026, 05:34 UTC

Utili

Sanofi Backs 2026 View

23 apr 2026, 05:33 UTC

Utili

Sanofi 1Q Business Net Pft EUR2.26B

23 apr 2026, 05:33 UTC

Utili

Analysts Saw Sanofi 1Q Business Oper Pft at EUR2.85B

23 apr 2026, 05:33 UTC

Utili

Sanofi 1Q Business Oper Pft EUR2.97B

23 apr 2026, 05:32 UTC

Utili

Analysts Saw Sanofi 1Q Net Sales at EUR10.22B

23 apr 2026, 05:32 UTC

Utili

Sanofi 1Q Net Sales Rose 14% on Year at Constant Exchange Rates

23 apr 2026, 05:31 UTC

Utili

Sanofi 1Q Net Sales EUR10.51B

10 apr 2026, 11:12 UTC

Discorsi di Mercato

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

10 apr 2026, 10:54 UTC

Discorsi di Mercato

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

30 mar 2026, 10:40 UTC

Discorsi di Mercato

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

27 mar 2026, 10:40 UTC

Discorsi di Mercato

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

11 mar 2026, 11:02 UTC

Discorsi di Mercato

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

24 feb 2026, 14:00 UTC

Acquisizioni, Fusioni, Takeovers

This Small-Cap Biotech Stock Is Soaring 35% on Excitement Over Its Prostate Cancer Drug -- Barrons.com

13 feb 2026, 08:21 UTC

Discorsi di Mercato

Sanofi's CEO Change Adds to Near-Term Uncertainty -- Market Talk

12 feb 2026, 15:20 UTC

Utili

Sanofi Shares Fall After CEO Change -- Update

10 feb 2026, 14:07 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Set Out $2.2 Bln Cash Deal for Dynavax Late Last Year

10 feb 2026, 14:06 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi: Acquisition Includes Dynavax's Hepatitis B Vaccine, Shingles Vaccine Candidate

10 feb 2026, 14:05 UTC

Acquisizioni, Fusioni, Takeovers

Sanofi Completes Acquisition of Dynavax

10 feb 2026, 14:00 UTC

Acquisizioni, Fusioni, Takeovers

Press Release: Sanofi Completes The Acquisition Of Dynavax >SAN.FR

6 feb 2026, 12:35 UTC

Utili

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio. -- Barrons.com

29 gen 2026, 13:00 UTC

Discorsi di Mercato

Utili

Sanofi Results Encourage, But Pipeline Strategy Should Take Priority -- Market Talk

Confronto tra pari

Modifica del prezzo

Sanofi Previsione

Obiettivo di Prezzo

By TipRanks

22.26% in crescita

Previsioni per 12 mesi

Media 53 USD 22.26%

Alto 57 USD

Basso 50 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Sanofi - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

3 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 3 che hanno fornito valutazioni azionarie a Sanofi - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

51.665 / 52.38Supporto e resistenza

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.